The initial phase of the study will involve a 2-month trial period in which the ClearSight/Nexfin device will be used for all consented patients. This period will allow for all providers to become familiar with the device and determine the logistics for which outpatient setting will be best suited to have the two study devices available during the week. In addition, the health care provider will fill out a survey (included with this submission) for each consented patient, evaluating the utility of this device. As this technology is a limited resource (only 2 devices available), the survey will allow the research team to determine which providers and which clinical settings will maximize its utility to carry out the below described study protocol.